Search research articles
Contact Us
Filters
Showing results (71-80 of 118) with videos related to
Page
of 12
Sort By:
Clinical Trials (London, England)
|
August 15, 2019
Noninferiority trials with nonadherence to the assigned randomized treatment
Edward L Korn, Robert J Gray, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Overall survival as the outcome for randomized clinical trials with effective subsequent therapies
Edward L Korn, Boris Freidlin, Jeffrey S Abrams
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2023
Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease
Boris Freidlin, Larissa A Korde, Edward L Korn
Journal of the National Cancer Institute
|
December 19, 2022
Dose optimization during drug development: whether and when to optimize
Edward L Korn, Jeffrey A Moscow, Boris Freidlin
Journal of the National Cancer Institute
|
August 20, 2015
Design Issues in Randomized Clinical Trials of Maintenance Therapies
Boris Freidlin, Richard F Little, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2018
Bias, Operational Bias, and Generalizability in Phase II/III Trials
Boris Freidlin, Edward L Korn, Jeffrey S Abrams
JAMA Oncology
|
May 12, 2017
Myeloma Minimal Residual Disease and Surrogacy
Richard F Little, Lisa M McShane, Boris Freidlin
Journal of the National Cancer Institute
|
January 16, 2010
Randomized clinical trials with biomarkers: design issues
Boris Freidlin, Lisa M McShane, Edward L Korn
Science Translational Medicine
|
March 29, 2013
Statistical challenges in the evaluation of treatments for small patient populations
Edward L Korn, Lisa M McShane, Boris Freidlin
The New England Journal of Medicine
|
March 30, 2012
Bevacizumab in ovarian cancer
Edward L Korn, Boris Freidlin, Jeffrey S Abrams
Page
of 12
Search research articles
Search
Showing results (71-80 of 118) with videos related to
Sort By:
Page
of 12
Clinical Trials (London, England)
|
August 15, 2019
Noninferiority trials with nonadherence to the assigned randomized treatment
Edward L Korn, Robert J Gray, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Overall survival as the outcome for randomized clinical trials with effective subsequent therapies
Edward L Korn, Boris Freidlin, Jeffrey S Abrams
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2023
Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease
Boris Freidlin, Larissa A Korde, Edward L Korn
Journal of the National Cancer Institute
|
December 19, 2022
Dose optimization during drug development: whether and when to optimize
Edward L Korn, Jeffrey A Moscow, Boris Freidlin
Journal of the National Cancer Institute
|
August 20, 2015
Design Issues in Randomized Clinical Trials of Maintenance Therapies
Boris Freidlin, Richard F Little, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2018
Bias, Operational Bias, and Generalizability in Phase II/III Trials
Boris Freidlin, Edward L Korn, Jeffrey S Abrams
JAMA Oncology
|
May 12, 2017
Myeloma Minimal Residual Disease and Surrogacy
Richard F Little, Lisa M McShane, Boris Freidlin
Journal of the National Cancer Institute
|
January 16, 2010
Randomized clinical trials with biomarkers: design issues
Boris Freidlin, Lisa M McShane, Edward L Korn
Science Translational Medicine
|
March 29, 2013
Statistical challenges in the evaluation of treatments for small patient populations
Edward L Korn, Lisa M McShane, Boris Freidlin
The New England Journal of Medicine
|
March 30, 2012
Bevacizumab in ovarian cancer
Edward L Korn, Boris Freidlin, Jeffrey S Abrams
Page
of 12